Dyne Therapeutics, Inc.
0 products tracked · names used in filings: Dyne Therapeutics, Inc.
Upcoming milestones
z-rostudirsen: PDUFA target action date (exon 51 Duchenne muscular dystrophy (DMD))
Dyne Therapeutics, Inc. (DYN); zeleciment rostudirsen; BLA; status: set; "Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 - - Additional one-year clinical data from…"; filed 2026-11-05 · source
Recent milestones
No recent milestones.
Products
No products recorded.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.